BioNTech (NASDAQ:BNTX) Given a $150.00 Price Target at Wells Fargo & Company

Key Points

• Wells Fargo & Company has cut its price target for BioNTech from $170.00 to $150.00, maintaining an "overweight" rating, suggesting a 36.12% upside from the previous close.
• Multiple analysts have varied outlooks on BioNTech, with a consensus rating of "Moderate Buy" and an average target price of $135.91.
• BioNTech reported a quarterly revenue increase of 102.6% year-over-year, despite missing earnings estimates with a loss of ($1.60) EPS.

BioNTech (NASDAQ:BNTX - Get Free Report) has been given a $150.00 target price by equities research analysts at Wells Fargo & Company in a research report issued on Tuesday, Marketbeat Ratings reports. The brokerage presently has an "overweight" rating on the stock. Wells Fargo & Company's target price points to a potential upside of 34.77% from the stock's current price.

Several other equities research analysts have also recently commented on the company. The Goldman Sachs Group initiated coverage on BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective on the stock. Truist Financial reiterated a "buy" rating and issued a $155.00 price target (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Leerink Partners set a $112.00 target price on shares of BioNTech in a report on Monday, June 2nd. JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, Citigroup reiterated a "buy" rating and set a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $135.91.

BioNTech Stock Up 0.2%

BNTX traded up $0.23 during midday trading on Tuesday, reaching $111.30. The company's stock had a trading volume of 1,181,001 shares, compared to its average volume of 660,929. The stock's 50-day moving average is $108.59 and its 200-day moving average is $106.20. BioNTech has a 1 year low of $78.39 and a 1 year high of $131.49. The firm has a market capitalization of $26.76 billion, a price-to-earnings ratio of -69.56 and a beta of 1.23. The company has a current ratio of 8.61, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The company had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%. BioNTech's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($3.36) EPS. As a group, research analysts expect that BioNTech will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise bought a new position in shares of BioNTech during the 1st quarter valued at approximately $36,000. LRI Investments LLC raised its stake in shares of BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after acquiring an additional 312 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of BioNTech by 472.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock worth $61,000 after acquiring an additional 472 shares during the last quarter. Banque Transatlantique SA bought a new position in BioNTech during the 1st quarter valued at about $80,000. Finally, Costello Asset Management INC purchased a new stake in BioNTech in the 1st quarter worth about $91,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.